Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy leads to lower overall survival compared with placebo, best supportive care (BSC) or no treatment (high certainty).
1 finding from 1 review
Progression‐free survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy probably leads to lower progression‐free survival compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
1 finding from 1 review
Serious adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy showed no clear difference in serious adverse events compared with placebo, best supportive care (BSC) or no treatment (low certainty).
1 finding from 1 review
Tumour response · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy may leads to higher tumour response rate compared with placebo, best supportive care (BSC) or no treatment (low certainty).
1 finding from 1 review
Daytime sleepiness (ESS): change from baseline. · adults with obstructive sleep apnoea
1 finding from 1 review
Adherence · adults with obstructive sleep apnoea
1 finding from 1 review
Adverse effects Measured as number of participants who discontinued device at end of 2 months · adults with obstructive sleep apnoea
1 finding from 1 review
Quality of life Assessed using SF‐36 or FOSQ · adults with obstructive sleep apnoea
1 finding from 1 review
Sleep quality Assessed by average duration of slow‐wave and REM sleep periods · adults with obstructive sleep apnoea
1 finding from 1 review
Cognitive dysfunction · adults with obstructive sleep apnoea
1 finding from 1 review
AHI · adults with obstructive sleep apnoea
1 finding from 1 review
Self‐reported adherence time · adults with obstructive sleep apnoea
1 finding from 1 review
Adverse effects · adults with obstructive sleep apnoea
1 finding from 1 review
Quality of life Assessed using SF‐36 or FOSQ · adults with obstructive sleep apnoea
1 finding from 1 review
Sleep quality Assessed by average duration of slow‐wave and REM sleep periods · adults with obstructive sleep apnoea
1 finding from 1 review
Cognitive dysfunction · adults with obstructive sleep apnoea
1 finding from 1 review
Daytime sleepiness (ESS): change from baseline. · adults with obstructive sleep apnoea
1 finding from 1 review
AHI · adults with obstructive sleep apnoea
1 finding from 1 review
Proportion of participants cleared or almost cleared ‐ · chronic palmoplantar pustulosis
1 finding from 1 review
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found